Literature DB >> 15925771

Increased circulating T cell reactivity to GM1 ganglioside in patients with Guillain-Barré syndrome.

Peter A Csurhes1, Alice-Ann Sullivan, Kerryn Green, Judith M Greer, Michael P Pender, Pamela A McCombe.   

Abstract

This study was performed to determine whether increased ganglioside-specific T cell reactivity can be detected in the peripheral blood of patients with Guillain-Barre syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). T cell responsiveness to the gangliosides GM1, GM3, GD1a, GD1b, GD3, GT1b, GQ1b and sulphatide was assessed in peripheral blood mononuclear cells from untreated GBS patients (57), CIDP patients (43), patients with other peripheral neuropathies (55) and healthy control subjects (74) in a standard 6-day proliferation assay. Increased T cell reactivity to GM1 occurred in GBS patients compared to healthy controls and patients with other neuropathies. There was increased reactivity to GM3 in GBS patients compared to patients with other neuropathies but not compared to healthy controls. The frequencies of increased T cell reactivity to GM1 and GM3 in CIDP patients were intermediate between those of GBS patients and controls. We suggest that T cell reactivity to gangliosides might play a contributory role in the pathogenesis of GBS and perhaps CIDP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15925771     DOI: 10.1016/j.jocn.2004.04.006

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  3 in total

1.  A case of fatal Guillain-Barre syndrome from anti-PD1 monoclonal antibody use.

Authors:  Aasems Jacob; Dileep C Unnikrishnan; Aju Mathew; Braghadheeswar Thyagarajan; Shil Patel
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-17       Impact factor: 4.553

Review 2.  The role of cytokines in Guillain-Barré syndrome.

Authors:  Ming-Ou Lu; Jie Zhu
Journal:  J Neurol       Date:  2010-11-23       Impact factor: 4.849

3.  Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy.

Authors:  H R Inglis; P A Csurhes; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-08       Impact factor: 10.154

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.